Holen Sie sich die Stockscreener-App
57.93
0.38%
0.22
Spruce Biosciences Inc Aktie (SPRB) Neueste Nachrichten
Guggenheim initiates coverage on Spruce Biosciences with Buy rating - scanx.trade
Spruce (SPRB) Q2 2026 Earnings: The Bottom-Line Figure Trails Its Comparison in the Latest Session; Reaction Snapshot: Shares Finish 0.14% Lower in the Current UpdateNon-GAAP Earnings - vinanet.vn
Spruce Biosciences receives $5.5M from patient advocacy groups By Investing.com - Investing.com Nigeria
Guggenheim lowers Spruce Biosciences stock price target to $104 By Investing.com - Investing.com South Africa
SPRB Maintained by Guggenheim -- Price Target Lowered to $104 - GuruFocus
Guggenheim lowers Spruce Biosciences stock price target to $104 - Investing.com
Spruce Biosciences (SPRB) Climbs 5.77% to $52.64 as Momentum Builds Toward $55.27 ResistanceBPI Reversal - vinanet.vn
Spruce Biosciences (NASDAQ:SPRB) Downgraded to Strong Sell Rating by Wall Street Zen - MarketBeat
OrbiMed discloses 7.3% ownership of Spruce Biosciences (SPRB) common stock - Stock Titan
Spruce Biosciences | SCHEDULE 13G: Others - Moomoo
Spruce Biosciences | SCHEDULE 13G/A: Others - Moomoo
Spruce Biosciences (SPRB): ADAR1, Schneeberger disclose 2.5% beneficial stake - Stock Titan
Citadel entities and Kenneth Griffin (SPRB) report 1.9% beneficial stake in Spruce - Stock Titan
Spruce Biosciences (SPRB) sees AWM Investment disclose 5.1% equity stake - Stock Titan
SPRB Maintained by Citizens -- Price Target Lowered to $144 - GuruFocus
Craig-Hallum Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Maintains Target Price $140 - Moomoo
Spruce Biosciences (NASDAQ:SPRB) Given New $144.00 Price Target at Citizens Jmp - MarketBeat
Spruce Biosciences (SPRB) Rises 1.42% as Shares Approach Key Resistance at $49.42Extension Target - vinanet.vn
Citizens cuts Spruce Biosciences stock price target on share dilution By Investing.com - Investing.com Australia
Citizens cuts Spruce Biosciences stock price target on share dilution - Investing.com
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - biospace.com
Spruce Biosciences (NASDAQ:SPRB) Issues Quarterly Earnings Results, Misses Estimates By $0.89 EPS - MarketBeat
Spruce Biosciences Q2 Results: EPS Misses Estimate, Losses Widen 91% YoY - scanx.trade
Spruce Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Form 8K Spruce Biosciences Inc For: 12 August By Investing.com - Investing.com South Africa
Spruce Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Spruce Biosciences, Inc. (SPRB) Stock Price, News, Quote & History - Yahoo! Finance Canada
SPRUCE BIOSCIENCES, INC. 2Q 2026: Net loss $(16.2M), EPS $(6.68) — 10-Q Summary - TradingView
SPRB: TA-ERT BLA submission and confirmatory study set for Q4 2026, with strong cash reserves and new leadership - TradingView
Spruce Biosciences reports Q2 2026 net loss $16.2M, cash $96.3M; BLA for TA-ERT expected Q4 2026 - TradingView
Spruce Biosciences Q2 2026 Results: Expenses Rise Ahead of the TA-ERT Filing - TradingKey
SPRB: Q2 2026 net loss rose to $16.2M as R&D spending surged, with $96.3M in cash on hand - TradingView
Spruce Biosciences (SPRB) ramps TA-ERT spend while lifting cash to $96.3M - Stock Titan
Spruce Biosciences posts $16.2 million Q2 net loss - Quiver Quantitative
Spruce Biosciences Q2 net loss widens on higher expenses - TradingView
8-K: Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updatesmoomoo - Moomoo
Spruce Biosciences (SPRB) doubles cash as TA-ERT BLA and $5.5M backing advance - Stock Titan
Spruce Biosciences receives $5.5M from patient advocacy groups - Investing.com
Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences - Yahoo Finance
Spruce Biosciences, Inc. announced that it has received $5.500192 million in funding - marketscreener.com
SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy - Stocktwits
Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - The National Law Review
Spruce Biosciences, Inc. announced that it expects to receive $5.500192 million in funding - marketscreener.com
Spruce Biosciences (SPRB) to Announce Quarterly Earnings on Thursday - MarketBeat
BlackRock, Inc. Adds to Spruce Biosciences Inc (SPRB) Position -- Shares Look 1032% Overvalued on GF Value - GuruFocus
Millennium entities and Israel Englander report 160,981 SPRB shares in joint filing - Stock Titan
Spruce Biosciences names Jessica Cohen Pfeffer as VP of development By Investing.com - Investing.com Nigeria
Spruce Biosciences Appoints Jessica Cohen Pfeffer as Vice President of Clinical Development - citybiz
Spruce Biosciences names Jessica Cohen Pfeffer as VP of development - Investing.com
Spruce Biosciences (SPRB) Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 4.6%Analyst Earnings Estimate - dars.gov.et
Form 4 Spruce Biosciences Inc For: 30 July By Investing.com - Investing.com Canada
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Grant of 13,000 RSUs to Spruce Biosciences (SPRB) Chief Medical Officer - Stock Titan
Spruce Biosciences Names Adrian Quartel Chief Medical Officer - The Globe and Mail
Spruce Biosciences names Adrian Quartel as CMO - The Pharma Letter
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):